Evidence map›Paper›PMID 32843459›Full record

ArticleBMJ case reports2020

Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma.

Shakthi Bhaskar, Brooj Abro, Tyler J Fraum, Neha Mehta-Shah

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shakthi BhaskarDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Brooj AbroDepartment of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA.
Tyler J FraumDepartment of Radiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Neha Mehta-ShahDepartment of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA mehta-n@wustl.edu.
Washington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL and its role in treatment.

Indexed as

Aged, 80 and overAnaplastic Lymphoma KinaseFemaleHumansImmunologic FactorsLenalidomideLymphoma, Large-Cell, AnaplasticTreatment OutcomeAnaplastic Lymphoma KinaseImmunologic FactorsLenalidomidecancer interventiontherapeutic indications

Identifiers

PMID32843459
PMCPMC7449333
OpenAlexW3081443860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.